All In Biotech

Drug Trial Radar · NCT01968109

An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

A Phase I/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Apr 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,482 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,482

Actual

Start

Nov 5, 2013

Primary completion

May 22, 2024

Study completion Feb 3, 2025

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Oct 23, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to assess the safety, tolerability and effectiveness of experimental medication BMS-986016 administered alone and in combination with nivolumab in patients with solid tumors that have spread and/or cannot be removed by surgery. The following tumor types are included in this study: Non-Small Cell Lung Cancer (NSCLC), gastric cancer, hepatocellular carcinoma, renal cell carcinoma, bladder cancer, squamous cell carcinoma of the head and neck, and melanoma, that have NOT previously been treated with immunotherapy. NSCLC and melanoma that HAVE previously been treated with immunotherapy.

Conditions

  • Neoplasms by Site

Interventions

  • RelatlimabBiological

  • NivolumabBiological

  • BMS-986213Biological

    Relatlimab + Nivolumab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events, Deaths and Clinically Relevant Laboratory AbnormalitiesTime frame: From first dose and within 135 days after last dose of study therapy (Up to approximately 82 months)
  2. Part C, D1, D2, E - Objective Response Rate Per BICRTime frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 127 months)
  3. Part C, D1, D2, E - Disease Control Rate (DCR) Per BICRTime frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 127 months)
  4. Part C, D1, D2, E - Duration of Response (DOR) Per BICRTime frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 127 months)
  5. Part D1: Number of Participants With Adverse Events in the Broad Scope Standardized MedDRA (SMQ) Anaphylactic Reaction Occurring Within 2 Days of Any Doses of Study TherapyTime frame: From first dose and within 2 days of first dose of study therapy
  6. Part C, D1, D2, E - Objective Response Rate Per BICRTime frame: From first dose (Day 1) and up to 97 months

Locations

54 sites in 15 countries. Site status is shown where the registry gives one.

  • Local Institution - 0043

    La Jolla, California

  • Local Institution - 0053

    Aurora, Colorado

  • Local Institution - 0058

    Tampa, Florida

  • Local Institution - 0003

    Chicago, Illinois

  • Local Institution - 0048

    Niles, Illinois

  • Local Institution - 0004

    Baltimore, Maryland

  • Local Institution - 0001

    Boston, Massachusetts

  • Local Institution - 0011

    Detroit, Michigan

  • Local Institution - 0051

    Rochester, Minnesota

  • Local Institution - 0044

    St Louis, Missouri

  • Local Institution - 0005

    New York, New York

  • Local Institution - 0002

    Portland, Oregon

  • Local Institution - 0047

    Allentown, Pennsylvania

  • Local Institution - 0010

    Pittsburgh, Pennsylvania

  • Local Institution - 0057

    Dallas, Texas

  • Local Institution - 0045

    Houston, Texas

  • Local Institution - 0008

    Seattle, Washington

  • Local Institution - 0029

    North Sydney, New South Wales, Australia

  • Local Institution - 0031

    Brisbane, Queensland, Australia

  • Local Institution - 0039

    Southport, Queensland, Australia

  • Local Institution - 0033

    Melbourne, Victoria, Australia

  • Local Institution - 0032

    Nedlands, Western Australia, Australia

  • Local Institution - 0023

    Vienna, Austria

  • Local Institution - 0024

    Vienna, Austria

  • Local Institution - 0049

    Toronto, Ontario, Canada

  • Local Institution - 0050

    Québec, Quebec, Canada

  • Local Institution - 0028

    Copenhagen, Denmark

  • Local Institution - 0020

    Herlev, Denmark

  • Local Institution - 0021

    Helsinki, Uusimaa, Finland

  • Local Institution - 0038

    Marseille, France

  • Local Institution - 0037

    Nantes, France

  • Local Institution - 0036

    Pierre-Bénite, France

  • Local Institution - 0026

    Toulouse, France

  • Local Institution - 0018

    Villejuif, France

  • Local Institution - 0007

    Essen, Germany

  • Local Institution - 0040

    Heilbronn, Germany

  • Local Institution - 0041

    Würzburg, Germany

  • Local Institution - 0014

    Milan, Italy

  • Local Institution - 0013

    Naples, Italy

  • Local Institution - 0035

    Padova, Italy

Showing 40 of 54 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.